Symposium

Welcome to our exciting symposium on precision cancer medicine in Helsinki!

Registration OPEN deadline  4.9.22  

Abstract submission OPEN deadline 12.6.22 

The two-day meeting will also have a poster session and social activities.

Confirmed speakers with tentative titles:

THURSDAY, SEPTEMBER 22

Keynotes/Special Lectures:

Kari Alitalo, University of Helsinki
TBC

Peter Kraft, Harvard University:
Polygenic risk scores and tailored cancer screening

Pasi Jänne, Dana-Farber Cancer Institute, Harvard Medical School:
Beyond the magic bullet

SESSIONS 1-3

Christian Meisel, Hedera Dx:
Actionable ctDNA based insights for precision cancer medicine

Jesus Banales, Biodonostia:
Genetic background of primary sclerosing cholangitis associated cholangiocarcinoma (PSC-CCA)

Cyriel Ponsioen, Amsterdam AMC:
Primary sclerosing cholangitis (PSC) dysplasia surveillance

Daniel Peeper, Netherlands Cancer Institute:
Rational concepts for tumor & immune cell therapy combinations

Marco Gerlinger, ICR The Institute of Cancer Research
TBC

Johanna Ivaska, University of Turku:
Stromal barriers to cancer progression

Francesca M. Buffa, University of Oxford:
Machine Learning and Systems Biology approaches in Precision Oncology

Pekka Katajisto, University of Helsinki:
NOTUM from Apc-mutant cells biases clonal competition to initiate cancer

FRIDAY SEPTEMBER 23

Keynotes/Special Lectures:

Bettina Ryll, Melanoma Patient Network Europe:
From good to great: What patients can do for your research?

SESSIONS 4-6

Karin de Visser, Netherlands Cancer Institute:
Innate-adaptive immune cell crosstalk dictates response to immune checkpoint blockade in breast cancer

Giulio Superti-Furga, CeMM, Medical University of Vienna:
Precision pharmacology and metabolic modulation in hematologic cancers

Kjetil Taskén, Institute of Cancer Research, Oslo University Hospital:
A national precision cancer medicine implementation initiative for Norway

Lynette Sholl, Brigham and Women’s Hospital/Harvard Medical School:
Molecular diagnostics of cancer to support individualized therapy: perspectives from a clinical lab

Prasad Adusumilli, Memorial Sloan Kettering Cancer Center:
CAR-T cell therapy for solid tumors; new opportunities and challenges

Åslaug Helland, Oslo University Hospital:
Personalized medicine in thoracic oncology; where are we now and where we are going – where we have the most to gain?

Dario Campana, NUS Yong Loo Lin School of Medicine:
Disrupting the treatment of lymphoid malignancies with CAR-T cells

Maria Themeli, Amsterdam UMC:
Designing optimal dual-targeting of CAR T cells: the BETTER gate

Satu Mustjoki, University of Helsinki:
Mechanisms of natural killer cell immune evasion by functional immune profiling

Organising committee:

Johanna Arola,  chair

Tomi Mäkelä, vice chair

Caroline Heckman

Päivi Ojala

Sirpa Leppä

Ilkka Ilonen
Secretariat:

Tiina Vesterinen, FCI

Leena Karhinen, iCAN

Satu Sankkila, iCAN

Saija Piiroinen, iCAN

Contact: ican-fci@helsinki.fi